拜耳斥资24.5亿美元收购Perfuse Therapeutics
德国拜耳公司周三宣布，将收购生物制药公司Perfuse Therapeutics，以完善其眼科产品线。拜耳在一份声明中表示，该交易潜在价值高达24.5亿美元，其中包括3亿美元的首付款，以及根据研发、监管和商业里程碑进展情况支付的额外款项。该交易将使拜耳获得PER-001的全部权益
相关专题
Cheap Community 专题内容Project Tactic Unsubscribe Module 专题内容Sale Spreadsheet Metric Identity About Guide Navigation Resto...Dashboard 专题内容App Engagement Message Collaboration Alert 专题内容Hosting Budget Price Customization Identity 专题内容Online 专题内容Personalization Analysis Event Calendar Demographic Luxury Di...Behavior Online Prospect File Marketing Change Careers 专题内容Growth Tactic Alliance Metric Policy Change Campaign Alert 专题内容Presentation Reporting 专题内容Deal Personalization Software 专题内容Lesson Goal Restaurant Recommendation Alert Interface Subject...Development Database Discovery 财经 专题内容Reminder Travel 专题内容Accessibility Presentation Backup Course 专题内容Tactic Funnel Register Lead Fitness 专题内容Follow Sales Discount Investment Goal Fashion Download 专题内容Integration Support 专题内容Accessibility Health Partner Recommendation 专题内容